Non‐invasive diagnosis and surveillance of bladder cancer with driver and passenger DNA methylation in a prospective cohort study
Clinical and Translational Medicine2022Vol. 12(8), pp. e1008–e1008
Citations Over TimeTop 10% of 2022 papers
Yu Xiao, Lingao Ju, Kaiyu Qian, Wan Jin, Gang Wang, Yan Zhao, Wei Jiang, Nan Liu, Kaichun Wu, Min‐Sheng Peng, Rui Cao, Sheng Li, Hongjie Shi, Yan Gong, Hang Zheng, Tongzu Liu, Yongwen Luo, Haoli Ma, Luyuan Chang, Gang Li, Xinyue Cao, Ye Tian, Zilin Xu, Zhonghua Yang, Liuying Shan, Zhongqiang Guo, Dongai Yao, Xianlong Zhou, Xintong Chen, Zicheng Guo, Dongmei Liu, Song Xu, Chundong Ji, Yu Fang, Xin Hong, Jun Luo, Hong Cao, Yi Zhang, Xinghuan Wang
Abstract
With the discovery of BLCA-specific DNAm signatures, targeted sequencing of ctDNA methylation outperforms FISH and DNA mutation to detect tumours, predict recurrence and make prognoses.
Related Papers
- → Targeting splicing factors as molecular non-muscle invasive bladder cancer predictors(2018)1 cited
- → Active Surveillance in Non-Muscle Invasive Bladder Cancer(2019)1 cited
- → Global DNA Methylation is influenced by smoking behavior(2007)
- → The Molecular Basis of Muscle Invasive Bladder Cancer(2021)
- → Xpert bladder cancer monitor in the follow up of patients affected by non muscle invasive bladder cancer (NMIBC): An update(2019)